• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lifeward Announces CEO Transition

    2/19/25 9:10:48 AM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email

    CEO Larry Jasinski to Retire

    Company Begins Search for New Leader to Drive Next Phase of Growth

    Company Provides Preliminary Full-Year 2024 Revenue

    Reschedules Virtual Investor Event Until Later in 2025 After Hiring of New CEO

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, the Company's Chief Executive Officer, will step down after a distinguished 13-year career at the Company. Mr. Jasinski will continue to serve in his existing roles through the second quarter of 2025 to assist with a transition to a successor.

    The Lifeward Board has appointed a special committee to direct the search for the Company's next CEO and will consider external and internal candidates, in partnership with a nationally recognized firm.

    Due to the CEO transition, Lifeward will reschedule its planned February 20th virtual investor event until later in 2025 after the hiring of the new CEO. The Company expects to report revenue for the year ended December 31, 2024 of approximately $25.7 million, aligning with its guidance range of $25 million to $26 million. Additionally, the Company expects annual GAAP operating expenses to be approximately $33.4 million, including about $5.7 million in restructuring and impairment expenses. These preliminary financial results have not been audited and are subject to adjustment based on the Company's completion of year-end financial close processes. The Company plans to provide its financial outlook for 2025 on its fourth-quarter and full-year 2024 financial results conference call to be scheduled during the week of March 10, 2025.

    "On behalf of the entire board of directors, we sincerely thank Larry for his unwavering dedication to the Company and the people we serve," said Joseph Turk, Chairman of the Lifeward Board of Directors. "Larry has been a true champion in the pursuit of our mission to provide access to technology that changes lives of people with physical limitations or disabilities. We look forward to collaborating with him in the months ahead to ensure a smooth transition and wish him the very best."

    Mr. Jasinski said, "I have been thrilled and honored to have led a remarkable team in creating a new industry that allowed the paralyzed community the ability to walk in everyday life. I am grateful and thank all the individuals I worked with on this journey. The ReWalk team shepherded a concept to a working device, compiled extensive scientific data, secured regulatory approvals, established capacity to supply, and importantly – delivered patients access to technology through payment coverage by Medicare, German insurers and others. Simply put, we changed lives. We added the unique AlterG Anti-Gravity systems, Soft Exo-Suit technology with the ReStore stroke system and the MyoCycle FES system to the portfolio which form a solid foundation for Lifeward's financial future."

    About Lifeward

    Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the MyoCycle FES System, and the ReStore Exo-Suit. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit GoLifeward.com.

    Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.

    Forward-Looking Statements

    The preliminary financial results for the year ended December 31, 2024 included in this press release are preliminary, unaudited and subject to completion. Such preliminary results are subject to the finalization of year-end financial and accounting procedures, and actual results may vary from the preliminary results presented herein. The preliminary financial results represent management estimates that constitute forward-looking statements subject to risks and uncertainties. These preliminary estimates have not been audited by Lifeward's independent registered public accounting firm.

    In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include Lifeward's preliminary financial results, projections regarding Lifeward's future performance and future regulatory interactions and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Lifeward's control. Important factors that could cause the Company's actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in the Company's periodic filings with the Securities and Exchange Commission ("SEC"), including the risk factors described under the heading "Risk Factors" in the Company's annual report on Form 10-K and 10-K/A for the year ended December 31, 2023 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, Lifeward undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

    Lifeward Media Relations:

    Kathleen O'Donnell

    VP Marketing & New Business Development

    Lifeward Ltd.

    E: [email protected]

    Lifeward Investor Contact:

    Mike Lawless

    Chief Financial Officer

    Lifeward Ltd.

    E: [email protected]



    Primary Logo

    Get the next $LFWD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 8:55:09 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/27/24 8:03:53 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/26/24 7:07:36 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lind Global Fund Ii Lp sold $1,655,009 worth of Ordinary Shares (573,110 units at $2.89) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      1/8/25 5:20:52 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Richner Randel sold $7,214 worth of Ordinary Shares (4,285 units at $1.68) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 4:08:29 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 8:55:09 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Laidlaw initiated coverage on Lifeward with a new price target

      Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

      2/10/25 7:00:44 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifeward Names Mark Grant as New CEO

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

      5/19/25 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Present at Sidoti Virtual Investor Conference on May 21

      MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, Chief Executive Officer, will make a corporate presentation and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May 21-22, 2025. Joining him will be Mike Lawless, Chief Financial Officer. The presentation will begin at 10:00 AM EDT on May 21, 2025 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_5U4M2xfKTV2ItMDBl

      5/19/25 6:00:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Leadership Updates

    Live Leadership Updates

    See more
    • Lifeward Names Mark Grant as New CEO

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

      5/19/25 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Robert J. Marshall to Its Board of Directors

      MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the Board of Directors has approved the appointment of Robert J. Marshall Jr. as a new director effective November 2, 2024. As part of his duties as a director, Mr. Marshall will serve as Chairman of the Audit Committee. Mr. Marshall has had a long and accomplished finance career in the medical device industry. Currently, Mr. Marshall serves as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc., a publicly traded radiopharmaceut

      11/7/24 4:05:14 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Dr. Keith E. Tansey, MD, PhD, will be joining its Medical Affairs team as a consultant in the role of Director, Clinical Research. Dr. Tansey's responsibilities will include the development and stewardship of Lifeward's clinical research program, the advancement of key opinion leader opportunities, and iden

      9/10/24 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    SEC Filings

    See more
    • Lifeward Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Lifeward Ltd. (0001607962) (Filer)

      5/19/25 8:40:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • SEC Form S-3 filed by Lifeward Ltd.

      S-3 - Lifeward Ltd. (0001607962) (Filer)

      5/15/25 4:06:12 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Lifeward Ltd.

      10-Q - Lifeward Ltd. (0001607962) (Filer)

      5/15/25 9:00:43 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Financials

    Live finance-specific insights

    See more
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561International (

      5/7/25 4:30:25 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-3

      2/28/25 8:00:16 AM ET
      $LFWD
      Industrial Specialties
      Health Care